Dermavant Sci Drug Patent Portfolio
Dermavant Sci owns 1 orange book drug protected by 11 US patents Given below is the list of Dermavant Sci's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11497718 | Use of tapinarof for the treatment of atopic dermatitis | 13 Nov, 2039 | Active |
| US11590088 | Use of Tapinarof for the treatment of chronic plaque psoriasis | 13 Nov, 2039 | Active |
| US11938099 | Use of tapinarof for the treatment of atopic dermatitis | 13 Nov, 2039 | Active |
| US10647649 | Process for preparing tapinarof | 13 Nov, 2038 | Active |
| US11597692 | Process for preparing tapinarof | 13 Nov, 2038 | Active |
| US10195160 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
| US10426743 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
| US11458108 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
| US11612573 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
| US11617724 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
| US11622945 | Topical pharmaceutical compositions | 19 May, 2036 | Active |
Latest Legal Activities on Dermavant Sci's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Dermavant Sci.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Petition Requesting Trial | 13 May, 2024 | US11590088 |
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US10195160 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US10195160 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Oct, 2023 | US10647649 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US10195160 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US10195160 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 11 Apr, 2023 | US11622945 |
|
Recordation of Patent Grant Mailed
Critical
| 11 Apr, 2023 | US11622945 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 04 Apr, 2023 | US11617724 |
|
Recordation of Patent Grant Mailed
Critical
| 04 Apr, 2023 | US11617724 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 28 Mar, 2023 | US11612573 |
|
Recordation of Patent Grant Mailed
Critical
| 28 Mar, 2023 | US11612573 |
|
Email Notification
Critical
| 23 Mar, 2023 | US11622945 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Mar, 2023 | US10426743 |
|
Issue Notification Mailed
Critical
| 22 Mar, 2023 | US11622945 |
Dermavant Sci's Drug Patent Litigations
Dermavant Sci's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 23, 2024, against patent number US11590088. The petitioner Encube Ethicals Pvt. Ltd., challenged the validity of this patent, with Dermavant Sciences GmbH et al. as the respondent. Click below to track the latest information on how companies are challenging Dermavant Sci's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11590088 | April, 2024 | Pending | Dermavant Sciences GmbH et al. | Encube Ethicals Pvt. Ltd. |
Dermavant Sci Drug Patents' Oppositions Filed in EPO
Dermavant Sci drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 03, 2023, by Sandoz Ag. This opposition was filed on patent number EP16725243A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP16725243A | Feb, 2023 | SANDOZ AG | Granted and Under Opposition |
Dermavant Sci's Family Patents
Dermavant Sci Drug List
Given below is the complete list of Dermavant Sci's drugs and the patents protecting them.
1. Vtama
Vtama is protected by 11 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11497718 | Use of tapinarof for the treatment of atopic dermatitis |
13 Nov, 2039
(14 years from now)
| Active |
| US11590088 | Use of Tapinarof for the treatment of chronic plaque psoriasis |
13 Nov, 2039
(14 years from now)
| Active |
| US11938099 | Use of tapinarof for the treatment of atopic dermatitis |
13 Nov, 2039
(14 years from now)
| Active |
| US10647649 | Process for preparing tapinarof |
13 Nov, 2038
(13 years from now)
| Active |
| US11597692 | Process for preparing tapinarof |
13 Nov, 2038
(13 years from now)
| Active |
| US10195160 | Topical pharmaceutical compositions |
19 May, 2036
(11 years from now)
| Active |
| US10426743 | Topical pharmaceutical compositions |
19 May, 2036
(11 years from now)
| Active |
| US11458108 | Topical pharmaceutical compositions |
19 May, 2036
(11 years from now)
| Active |
| US11612573 | Topical pharmaceutical compositions |
19 May, 2036
(11 years from now)
| Active |
| US11617724 | Topical pharmaceutical compositions |
19 May, 2036
(11 years from now)
| Active |
| US11622945 | Topical pharmaceutical compositions |
19 May, 2036
(11 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vtama's drug page